Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2161-2180 of 3,900 trials

Endometrial Stromal Sarcoma: Aromatase Inhibitor Treatment Study

We are comparing the effects of stopping versus continuing aromatase inhibitors in patients with advanced low-grade endometrial stromal sarcoma. This study aims to find out which approach may help patients live longer without disease progression.

Low-Grade Endometrial Stroma Sarcoma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Gastrointestinal Stromal Tumors: Imatinib Treatment Study

We are exploring whether continuing or stopping imatinib treatment after 10 years benefits patients with advanced GISTs. The study looks at health outcomes like survival rates and quality of life.

Locally Advanced or Metastatic Gastrointestinal Stromal Tumors>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

X-Linked Hypohidrotic Ectodermal Dysplasia: ER004 Treatment

We are studying a new prenatal treatment for male infants with X-linked hypohidrotic ectodermal dysplasia to see if it improves sweating ability and dental health. The trial also examines the safety of this treatment for both the infants and their mothers.

X-linked Hypohidrotic Ectodermal Dysplasia≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyInternal MedicinePediatrics

Crohn's Disease: SAR441566 Treatment Study

We are investigating how different doses of SAR441566 affect symptoms and health in adults with moderate to severe Crohn's disease. This study aims to find out if the medication can help improve patients' quality of life and overall condition.

Crohn's Disease1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Mantle Cell Lymphoma: Ibrutinib and Venetoclax Study

We are studying the effects of Ibrutinib alone and in combination with Venetoclax in patients with untreated mantle cell lymphoma. The goal is to see how well these treatments reduce disease levels in the body.

Untreated Mantle Cell Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Infectious Pulmonary Endotheliopathy: Iloprost Infusion Study

We are investigating whether a continuous infusion of iloprost can help reduce the risk of death in mechanically ventilated patients with infectious pulmonary issues. This study compares the treatment to a placebo to assess its effectiveness.

Respiratory FailureInfectious Pulmonary Endotheliopathy>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesInternal MedicinePulmonology

Protecting Children from Radiation-Induced Hypothyroidism

We are studying whether TSH suppression during radiation therapy can lower the risk of hypothyroidism in children with medulloblastoma and lymphomas. This trial also examines any changes in thyroid tissue after treatment.

Hodgkin and Non-Hodgkin LymphomaMedulloblastoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesEndocrinologyOncology

Thyroid Eye Disease: Batoclimab Extension Study

We are studying the long-term effects of batoclimab in people with Thyroid Eye Disease who previously participated in earlier studies. The goal is to see if it continues to help reduce eye bulging and benefits those who didn't respond to earlier treatments.

Thyroid Eye Disease3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOphthalmology

IgA Nephropathy: Hydroxychloroquine Study

We are studying whether Hydroxychloroquine can help slow kidney function decline in patients with IgA Nephropathy. This trial focuses on those with high levels of protein in their urine despite current treatments.

IgA Nephropathy>2 yearsConfirmation phase (III)Standard MedicinesInternal MedicineNephrology

Sickle Cell Disease and β-Thalassemia: CTX001 Treatment Study

We are studying the long-term safety and effectiveness of a new CRISPR-based treatment for patients with β-thalassemia or severe sickle cell disease. This research aims to understand how well the treatment works over time.

Sickle Cell DiseaseTransfusion Dependent ThalassemiaConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematology

Stem Cell Transplant for Children with Acute Lymphoblastic Leukemia

We are studying different conditioning treatments for children and adolescents with acute lymphoblastic leukemia undergoing stem cell transplantation. Our goal is to find out which treatment leads to better survival and fewer side effects.

Acute Lymphoblastic Leukaemia1-2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesHematologyOncologyPediatrics

Cardio Renal Syndrome: Peritoneal Ultrafiltration Treatment

We are studying whether Peritoneal Ultrafiltration can help prevent heart failure worsening in patients with Cardio Renal Syndrome. The trial also looks at improvements in health and quality of life.

Congestive Heart Failure>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCardiologyInternal MedicineNephrology

Advanced Melanoma: EIK1001 and Pembrolizumab Study

We are studying a new treatment combining EIK1001 with pembrolizumab for patients with advanced melanoma. The goal is to see if this combination improves survival and slows disease progression compared to a placebo.

Advanced Melanoma1-2 yearsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesPartially RemoteOncology

Wiskott-Aldrich Syndrome: Gene Therapy Follow-Up

We are monitoring the long-term safety of a gene therapy in patients with Wiskott-Aldrich Syndrome who received a specific stem cell treatment. This study helps us understand how the therapy affects their health over time.

Wiskott-Aldrich Syndrome>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematology

Fosfomycin: New Extended Infusion Method

We are studying a new way to give fosfomycin to see if it improves how the body absorbs the medication. This trial is for individuals needing antibiotic treatment.

Healthy Participants>2 yearsSafety phase (I)Infectious Diseases

Bladder Cancer: Neoadjuvant Chemotherapy Study

We are testing whether bladder instillation of neoadjuvant chemotherapy can help prevent recurrence in patients with non-muscle-invasive bladder cancer. This study compares it to standard treatment to assess effectiveness and side effects.

Non-muscle invasive bladder cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOncologyUrology

Anticoagulant Treatments for Intra-Cardiac Thrombus: The ARGONAUT Trial

We are comparing a new direct oral anticoagulant with a standard vitamin K antagonist in patients with intra-cardiac thrombus. The goal is to see which treatment better reduces complications and promotes thrombus regression.

Intracardiac Thrombus>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

BCR-ABL1+ Chronic Myeloid Leukemia: Asciminib Treatment Study

We are studying Asciminib, alone or with Nilotinib, for adults with BCR-ABL1+ Chronic Myeloid Leukemia. The goal is to see if this treatment helps achieve better disease control and improves quality of life.

Chronic Myeloid Leukemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHematologyOncology

Systemic Juvenile Idiopathic Arthritis: Sarilumab Study

We are testing the medication sarilumab in children and adolescents with systemic juvenile idiopathic arthritis to find the best dose and understand its effects and safety.

Systemic Juvenile Idiopathic Arthritis (sJIA)3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePediatricsRheumatology

Relapsing Multiple Sclerosis: Obexelimab Study

We are testing a new medication, Obexelimab, to see if it helps prevent new brain lesions in people with relapsing multiple sclerosis. The study will also assess the safety of this treatment compared to a placebo.

Relapsing-Remitting Multiple Sclerosis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInternal MedicineNeurology